Prognostic role of metabolic syndrome in the elderly is not greater than the sum of its components

Aging Health

Volumn 6, Issue 2, 2010, Pages 217-228

  Mazza, Alberto ^a,b   Pessina, Achille C ^b   Zamboni, Sergio ^a   Casiglia, Edoardo ^b  

^a ROVIGO GENERAL HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cardiovascular risk; Elderly; Epidemiology; Hypertension; Metabolic syndrome

Indexed keywords

ANTIHYPERTENSIVE AGENT; FATTY ACID; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; AGED; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DYSLIPIDEMIA; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK REDUCTION;

EID: 77950121331     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.10.9     Document Type: Review

References (96)

1. Grundy SM, Brewer BH Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109, 433-438 (2004).
2. Day C: Metabolic syndrome, or what you will: definitions and epidemiology. Diab. Vasc. Dis. Res. 4, 32-38 (2007).
3. Saely CH, Rein P, Drexel H: The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. Horm. Metab. Res. 39, 642-650 (2007).
4. Hitzenberger K, Richter-Quittner M: Ein Beitrag zum Stoffwechsel bei der vaskularen Hypertonie. Wiener Arch. Innere Med. 2, 189-216 (1921).
5. Kylin E: Hypertension and diabetes. Zentralblatt Innere Med. 42, 873-877 (1921).
6. Marañon G: Severe hypertension and diabetes. Zentralblatt Innere Med. 43, 169-176 (1922).
7. Kylin E: Studies in the hypertension- hyperglycemia-hyperuricemia syndrome. Zentralblatt Innere Med. 44, 105-127 (1923).
8. Vague J: Sexual differentiation, a determining factor in obesity classes. Presse Med. 30, 339-340 (1947).
9. Avogaro P, Crepaldi G, Enzi G, Tiengo A: Association of hiperlipidemia, diabetes mellitus and moderate obesity. Acta Diabetol. Lat. 4, 36-41 (1967).
10. Reaven GM: Banting lecture. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
11. Grundy SM: Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. 47, 1093-1100 (2006).
12. Reaven GM: The metabolic syndrome: is this diagnosis necessary? Am. J. Clin. Nutr. 83, 1237-1247 (2006).
13. Reaven GM: The metabolic syndrome: requiescat in pace. Clin. Chem. 51, 931-938 (2005).
14. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289-2304 (2005).
15. Zamboni M, Mazzali G, Zoico E et al.: Health consequences of obesity in the elderly: a review of four unresolved questions. Int. J. Obes. 29, 1011-1029 (2005).
16. Natali A, Pucci G, Boldrini B, Schillaci G: Metabolic syndrome: at the crossroads of cardiorenal risk. J. Nephrol. 22, 29-38 (2009).
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-11421(2002).
18. Gulsvik AK, Thelle DS, Mowé M, Wyller TB: Increased mortality in the slim elderly: a 42 years follow-up study in a general population. Eur. J. Epidemiol. 24(11), 683-690 (2009).
19. Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat. Report 13, 1-7 (2009).
20. Park HS, Song YM, Cho SI: Obesity has a greater impact on cardiovascular mortality in younger men than in older men among non-smoking Koreans. Int. J. Epidemiol. 35, 181-187 (2006).
21. Ramsay SE, Whincup PH, Shaper AG, Wannamethee SG: The relations of body composition and adiposity measures to ill health and physical disability in elderly men. Am. J. Epidemiol. 164, 459-469 (2006).
22. Ohrvik J, Hedberg P, Jonason T, Lönnberg I, Nilsson G: Factor analysis of the individual components of the metabolic syndrome among elderly identifies two factors with different survival patterns - a population-based study. Metab. Syndr. Relat. Disord. 7, 171-177 (2009).
23. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet. Med. 15, 539-553 (1998).
24. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med. 16, 683-689 (1999).
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
26. Carr DB, Utzschneider KM, Hull RL et al.: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53, 2087-2097 (2004).
27. Bloomgarden ZT: American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 26, 933-939 (2003).
28. Arenare F, Quarti-Trevano F, Seravalle G, Mancia G: Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Prog. Cardiovasc. Dis. 52, 31-37 (2009).
29. Sowers JR, Whaley-Connell A, Epstein M: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 150, 776-783 (2009).
30. Redon J, Cifkova R, Laurent S et al.: Mechanisms of hypertension in the cardiometabolic syndrome. J. Hypertens. 27, 441-451 (2009).
31. Eckel RH: Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc. Nutr. Soc. 66, 82-95 (2007).
32. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association: Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 109, 551-556 (2004).
33. Deedwania P, Barter P, Carmena R et al.; Treating to New Targets Investigators: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368, 919-928 (2006).
34. Fagerberg B, Bondjers L, Nilsson PM: Low birth weight in combination with catch-up growth predicts the occurrence of the metabolic syndrome in men in late middle age. The Atherosclerosis and Insulin Resistance (AIR) study. J. Intern. Med. 256, 1-6 (2004).
35. Bruno G, Merletti F, Biggeri A et al.: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in Type 2 diabetes. The Casale Monferrato Study. Diabetes Care 27, 2689-2694 (2004).
36. Meigs JB, Williams K, Sullivan LM et al.: Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 27, 1417-1426 (2004).
37. Stern MP, Williams K, Gonzales-Villalpando C, Hunt K, Haffner SM: Does the metabolic syndrome improve identification of individuals at risk of Type 2 diabetes and/or cardiovascular disease? Diabetes Care 27, 2676-2681 (2004).
38. The DECODE Study Group; European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161, 397-404 (2001).
39. Takahashi N, Goto T, Hirai S, Uemura T, Kawada T: Genome science of lipid metabolism and obesity. Forum Nutr. 61, 25-38 (2009).
40. Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15, 2792-2800 (2004).
41. Erbay E, Cao H, Hotamisligil GS: Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome. Curr. Atheroscler. Rep. 9, 222-229 (2007).
42. Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D: Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr. Hypertens. Rep. 10, 131-137 (2008).
43. Flier JS: Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337-350 (2004).
44. Wassmann S, Stumpf M, Strehlow K et al.: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ. Res. 94, 534-541 (2004).
45. Thatcher S, Yiannikouris F, Gupte M, Cassis L: The adipose renin-angiotensin system: role in cardiovascular disease. Mol. Cell. Endocrinol. 302, 111-117 (2009).
46. Yang WS, Chuang LM: Human genetics of adiponectin in the metabolic syndrome. J. Mol. Med. 84, 112-121 (2006).
47. Oda E: The metabolic syndrome as a concept of adipose tissue disease. Hypertens. Res. 31, 1283-1291 (2009).
48. DeFronzo RA: Lilly lecture. The triumvirate: b-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37, 667-687 (1988).
49. Lowell BB, Shulman GI: Mitochondrial dysfunction and Type 2 diabetes. Science 307, 384-387 (2005).
50. Tanaka T, Yamamoto J, Iwasaki S et al.: Activation of peroxisome proliferator-activated receptor-d induces fatty acid b-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl Acad. Sci. USA 100, 15924-15929 (2003).
51. Defronzo RA: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of Type 2 diabetes mellitus. Diabetes 58, 773-795 (2009).
52. Kashyap S, Belfort R, Gastaldelli A et al.: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop Type 2 diabetes. Diabetes 52, 2461-2474 (2003).
53. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with Type 2 diabetes. N. Engl. J. Med. 350, 664-671 (2004).
54. Denys K, Cankurtaran M, Janssens W, Petrovic M: Metabolic syndrome in the elderly: an overview of the evidence. Acta Clin. Belg. 64, 23-34 (2009).
55. WHO: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. WHO, Austria (1999).
56. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
57. Casiglia E, Tikhonoff V, Mazza A, Pessina AC: Systolic and pulse hypertension. Aging Health 1, 1-9 (2005).
58. Jiamsripong P, Mookadam M, Alharthi MS, Khandheria BK, Mookadam F: The metabolic syndrome and cardiovascular disease: part 2. Prev. Cardiol. 11, 223-229 (2008).
59. Saad MF, Rewers M, Selby J et al.: Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension 43, 1324-1331 (2004).
60. Shen BJ, Todaro JF, Niaura R et al.: Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am. J. Epidemiol. 157, 701-711 (2003).
61. Mazza A, Zamboni S, Tikhonoff V et al.: Pulse hypertension: a new component of the metabolic syndrome in elderly women? J. Hum. Hypert. 21, 934-941 (2007).
62. Mazza A, Pessina AC, Tikhonoff V, Pavei A, Privato G, Casiglia E: Pulse pressure: an independent predictor of coronary and stroke mortality in elderly females from the general population. Blood Pressure 10, 205-211 (2001).
63. Casiglia E, Tikhonoff V, Mazza A, Piccoli A, Pessina AC: Pulse pressure and coronary mortality in elderly men and women from general population. J. Hum. Hypert. 16: 611-620 (2002).
64. Tikhonoff V, Casiglia E: Metabolic syndrome: nothing more than a constellation? Eur. Heart J. 28, 780-781 (2007).
65. Hillier TA, Rizzo JH, Pedula KL et al.: Increased mortality associated with the metabolic syndrome in older women with diabetes. Diabetes Care 28, 2258-2260 (2005).
66. Taddei S: Blood pressure through aging and menopause. Climacteric 12(Suppl. 1), 36-40 (2009).
67. Mazza A, Zamboni S, Tikhonoff V, Pessina AC, Casiglia E: Body mass index and mortality in elderly men and women from general population. The experience of Cardiovascular Study in the Elderly (CASTEL). Gerontology 53, 36-45 (2007).
68. Casiglia E, Palatini P: Cardiovascular risk factors in the elderly. J. Hum. Hypert. 12, 575-581 (1998).
69. Casiglia E, Spolaore P, Ginocchio G et al.: Predictors of mortality in very old subjects aged 80 years or over. The CASTEL (Cardiovascular Study in the Elderly). Eur. J. Epidemiol. 9, 577-586 (1993).
70. Kuk JL, Saunders TJ, Davidson LE, Ross R: Age-related changes in total and regional fat distribution. Ageing Res. Rev. 8, 339-348 (2009).
71. Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V: Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int. J. Obes. Relat. Metab. Disord. 28, 1018-1025 (2004).
72. Sundström J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L: Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 332, 878-882 (2006).
73. Sundström J, Vallhagen E, Riserus U et al.: Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 29, 1673-1674 (2006).
74. Butler J, Rodondi N, Zhu Y et al.: Metabolic syndrome and the risk of cardiovascular disease in older adults. J. Am. Coll. Cardiol. 47, 1595-1602 (2006).
75. Maggi S, Noale M, Gallina P et al.: Metabolic syndrome, diabetes, and cardiovascular disease in an elderly Caucasian cohort: the Italian Longitudinal Study on Aging. J. Gerontol. A Biol. Sci. Med. Sci. 61, 505-510 (2006).
76. Motta M, Bennati E, Cardillo E, Passamonte M, Ferlito L, Malaguarnera M: The metabolic syndrome in the elderly: considerations on the diagnostic criteria of the International Diabetes Federation and some proposed modifications. Arch. Gerontol. Geriatr. 48, 380-384 (2009).
77. Scuteri A, Najjar SS, Morrell CH, Lakatta EG: The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 28, 882-887 (2005).
78. McNeill AM, Katz R, Girman CJ et al.: Metabolic syndrome and cardiovascular disease in older people: the Cardiovascular Health Study. J. Am. Geriatr. Soc. 54, 1317-1324 (2006).
79. Ferrucci L, Alley D: Obesity, disability, and mortality: puzzling link. Arch. Intern. Med. 167, 750-751 (2007).
80. Dey DK, Lissner L: Obesity in 70-year-old subjects as a risk factor for 15-year coronary heart disease incidence. Obes. Res.11, 817-827 (2003).
81. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110, 380-385 (2004).
82. McNeill AM, Rosamond WD, Girman CJ et al.: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28, 385-390 (2005).
83. Malik S, Wong ND, Franklin SS et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245-1250 (2004).
84. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110, 1251-1257 (2004).
85. Wang J, Ruotsalainen S, Moilanen L, Depisto PI, Laakso M, Kuusisto J: The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur. Heart J. 28, 857-864 (2007).
86. Ren J, Kelley RO: Cardiac health in women with metabolic syndrome: clinical aspects and pathophysiology. Obesity 17, 1114-1123 (2009).
87. Zambon S, Zanoni S, Romanato G et al.: Metabolic syndrome and all-cause and cardiovascular mortality in an Italian elderly population: the Progetto Veneto Anziani (Pro.V.A.) study. Diabetes Care 32, 153-159 (2009).
88. Ravaglia G, Forti P, Maioli F et al.: Metabolic syndrome: prevalence and prediction of mortality in elderly individuals. Diabetes Care 29, 2471-2476 (2006).
89. Franks PW, Olsson T: Metabolic syndrome and early death: getting to the heart of the problem. Hypertension 49, 10-12 (2007).
90. Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS: Metabolic syndrome and mortality in older adults. The Cardiovascular Health Study. Arch. Intern. Med. 168, 969-978 (2008).
91. Ferdinand KC: Management of cardiovascular risk in patients with Type 2 diabetes mellitus as a component of the cardiometabolic syndrome. J. Cardiometab. Syndr. 1, 133-140 (2006).
92. Orchard TJ, Temprosa M, Goldberg R et al.; Diabetes Prevention Program Research Group: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142, 611-619 (2005).
93. Riddle MC, Drucker DJ: Emerging therapies mimicking the effects of amylin and glucagon-like peptide-1. Diabetes Care 29, 435-439 (2006).
94. Grant RW, Meigs JB: Should the insulin resistance syndrome be treated in the elderly? Drugs Aging 21, 141-151 (2004).
95. Lakka TA, Laaksonen DE, Lakka HM et al.: Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med. Sci. Sports Exerc. 35, 1279-1286 (2003).
96. Hassinen M, Lakka TA, Savonen K et al.: Cardiorespiratory fitness as a feature of metabolic syndrome in older men and women: the Dose-Responses to Exercise Training study. Diabetes Care 31, 1242-1247 (2008).